Clinical trial
A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
NCT01922843 is registered in ClinicalTrials.gov with Deltanoid Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
- Lead sponsor
- Deltanoid Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2013
- Completion date
- June 30, 2014
- Enrollment
- 62 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.